Equilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats

Bone

Volumn 53, Issue 1, 2013, Pages 59-68

  Hokugo, Akishige ^a   Sun, Shuting ^b   Park, Sil ^a   McKenna, Charles E ^b   Nishimura, Ichiro ^a  

^a UCLA SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adsorption; Bisphosphonate; Equilibrium; Fluorescence; Osteonecrosis of the jaw

Indexed keywords

6 CARBOXYFLUORESCEIN; 6 CARBOXYL X RHODAMINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM PHOSPHATE; CARBOXY TERMINAL COLLAGEN CROSSLINK; COLLAGEN; HYDROXYAPATITE; PHOSPHATASE; RHODAMINE; RISEDRONIC ACID; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BONE MINERAL; BONE REMODELING; CONTROLLED STUDY; DRUG ADSORPTION; DRUG BINDING; DRUG DISTRIBUTION; DRUG INTERACTION; DRUG MEGADOSE; IN VITRO STUDY; IN VIVO STUDY; JAW; JAW OSTEONECROSIS; LOW DRUG DOSE; NONHUMAN; OSTEOLYSIS; PROTEIN BLOOD LEVEL; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; VITAMIN D DEFICIENCY;

ANIMALS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT DYES; MINERALS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84871511367     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.11.030     Document Type: Article

References (45)

1. Russell R.G., Xia Z., Dunford J.E., Oppermann U., Kwaasi A., Hulley P.A., et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007, 1117:209-257.
2. Ebetino F.H., Hogan A.M., Sun S., Tsoumpra M.K., Duan X., Triffitt J.T., et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 2011, 49:20-33.
3. Peris P., Torra M., Olivares V., Reyes R., Monegal A., Martinez-Ferrer A., et al. Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. Bone 2011, 49:706-709.
4. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
5. Bauer D.C., Garnero P., Hochberg M.C., Santora A., Delmas P., Ewing S.K., et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006, 21:292-299.
6. Sebba A. Osteoporosis: how long should we treat?. Curr Opin Endocrinol Diabetes Obes 2008, 15:502-507.
7. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589.
8. van Beek E., Pieterman E., Cohen L., Lowik C., Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999, 264:108-111.
9. van Beek E., Pieterman E., Cohen L., Lowik C., Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 1999, 255:491-494.
10. Rogers M.J., Crockett J.C., Coxon F.P., Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011, 49:34-41.
11. Marx R.E., Cillo J.E., Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007, 65:2397-2410.
12. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
13. Ruggiero S.L. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development. J Oral Maxillofac Surg 2009, 67:13-18.
14. Reid I.R., Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol 2011, 8:90-96.
15. Hoff A.O., Toth B.B., Altundag K., Johnson M.M., Warneke C.L., Hu M., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008, 23:826-836.
16. Urade M., Tanaka N., Furusawa K., Shimada J., Shibata T., Kirita T., et al. Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg 2011, 69:e364-e371.
17. Barasch A., Cunha-Cruz J., Curro F.A., Hujoel P., Sung A.H., Vena D., et al. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res 2011, 90:439-444.
18. Allen M.R., Ruggiero S.L. Higher bone matrix density exists in only a subset of patients with bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 2009, 67:1373-1377.
19. Hellstein J.W., Adler R.A., Edwards B., Jacobsen P.L., Kalmar J.R., Koka S., et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2011, 142:1243-1251.
20. Kashemirov B.A., Bala J.L., Chen X., Ebetino F.H., Xia Z., Russell R.G., et al. Fluorescently labeled risedronate and related analogues: "magic linker" synthesis. Bioconjug Chem 2008, 19:2308-2310.
21. Laib A., Kumer J.L., Majumdar S., Lane N.E. The temporal changes of trabecular architecture in ovariectomized rats assessed by MicroCT. Osteoporos Int 2001, 12:936-941.
22. Hildebrand T., Ruegsegger P. A new method for the model-independent assessment of thickness in three-dimensional images. J Microsc 1997, 185:67-75.
23. Cao J.J., Wronski T.J., Iwaniec U., Phleger L., Kurimoto P., Boudignon B., et al. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J Bone Miner Res 2005, 20:1659-1668.
24. Sukotjo C., Lin A., Song K., Ogawa T., Wu B., Nishimura I. Oral fibroblast expression of wound-inducible transcript 3.0 (wit3.0) accelerates the collagen gel contraction in vitro. J Biol Chem 2003, 278:51527-51534.
25. Hokugo A., Christensen R., Chung E.M., Sung E.C., Felsenfeld A.L., Sayre J.W., et al. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res 2010, 25:1337-1349.
26. Roelofs A.J., Coxon F.P., Ebetino F.H., Lundy M.W., Henneman Z.J., Nancollas G.H., et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010, 25:606-616.
27. Sun S., Blazewska K.M., Kashemirov B.A., Roelofs A.J., Coxon F.P., Rogers M.J., et al. Synthesis and characterization of novel fluorescent nitrogen-containing bisphosphonate imaging probes for bone active drugs. Phosphorus Sulfur Silicon Relat Elem 2011, 186:970-971.
28. Vandersteenhoven J.J., DeLustro F.A., Bell N.H., Turner R.T. Osteoinduction by implants of demineralized allogeneic bone matrix is diminished in vitamin D-deficient rats. Calcif Tissue Int 1988, 42:39-45.
29. Turner R.T., Farley J., Vandersteenhoven J.J., Epstein S., Bell N.H., Baylink D.J. Demonstration of reduced mitogenic and osteoinductive activities in demineralized allogeneic bone matrix from vitamin D-deficient rats. J Clin Invest 1988, 82:212-217.
30. Henneman Z.J., Nancollas G.H., Ebetino F.H., Russell R.G., Phipps R.J. Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. J Biomed Mater Res A 2008, 85:993-1000.
31. Roelofs A.J., Stewart C.A., Sun S., Blazewska K.M., Kashemirov B.A., McKenna C.E., et al. Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. J Bone Miner Res 2012, 27:835-847.
32. Brown J.P., Albert C., Nassar B.A., Adachi J.D., Cole D., Davison K.S., et al. Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem 2009, 42:929-942.
33. Rosen H.N., Moses A.C., Garber J., Iloputaife I.D., Ross D.S., Lee S.L., et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000, 66:100-103.
34. Rissanen J.P., Suominen M.I., Peng Z., Halleen J.M. Secreted tartrate-resistant acid phosphatase 5b is a marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int 2008, 82:108-115.
35. Geng Z., Monier-Faugere M.C., Bauss F., Malluche H.H. Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. Clin Nephrol 2000, 54:45-53.
36. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
37. Turek J., Ebetino F.H., Lundy M.W., Sun S., Kashemirov B.A., McKenna C.E., et al. Bisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbits. Calcif Tissue Int 2012, 90:202-210.
38. Duan X. Physiological and biological mechanisms of bisphosphonate action. Medical Sciences Division 2010, University of Oxford, Oxford.
39. Cremers S.C., Papapoulos S.E., Gelderblom H., Seynaeve C., den Hartigh J., Vermeij P., et al. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Miner Res 2005, 20:1543-1547.
40. Kozloff K.M., Volakis L.I., Marini J.C., Caird M.S. Near-infrared fluorescent probe traces bisphosphonate delivery and retention in vivo. J Bone Miner Res 2010, 25:1748-1758.
41. Wen D., Qing L., Harrison G., Golub E., Akintoye S.O. Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate. Oral Dis 2011, 17:427-432.
42. Hansen T., Kunkel M., Weber A., James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006, 35:155-160.
43. Palaska P.K., Cartsos V., Zavras A.I. Bisphosphonates and time to osteonecrosis development. Oncologist 2009, 14:1154-1166.
44. Van den Wyngaert T., Huizing M.T., Vermorken J.B. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?. Ann Oncol 2006, 17:1197-1204.
45. Saad F., Brown J.E., Van Poznak C., Ibrahim T., Stemmer S.M., Stopeck A.T., et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012, 23:1341-1347.